Influence of supragingival biofilm control and smoking habit on Interleukin-1β concentration

Braz Oral Res. 2015;29(1):S1806-83242015000100302. doi: 10.1590/1807-3107BOR-2015.vol29.0115. Epub 2015 Oct 9.

Abstract

This investigation compared gingival crevicular fluid (GCF) interleukin-1β (IL-1β) concentrations in periodontitis patients subjected to a strict supragingival biofilm control (Supra) for 6 months. Never-smokers (23) and smokers (n = 20; 19.6 ± 11.8 cigarettes/day) moderate-to-severe chronic periodontitis patients underwent a 6 months period of supragingival control with weekly recall visits. Periodontal probing depth (PPD), bleeding on probing (BOP) and GCF samples (from different PPD category sites: 3-5 mm and 6-10 mm) were obtained at the baseline, 30, and 180 days. IL-1β was assessed by enzyme-linked immunosorbent assay. Generalized estimating equations were used to fit prediction models of IL-1β changes, considering the dependence between the examinations, and using only data from experimental sites. Overall IL-1β concentrations decreased from 3.2 pg/µL to 1.9 pg/µL. Higher baseline IL-1β concentrations were associated with higher baseline PPD values in both groups. There were no differences in IL-1β concentrations between never-smokers and smokers over time for any PPD category. Higher baseline PPD values and the presence of BOP on day 180 were significantly associated with higher IL-1β concentrations. A strict Supra regimen reduced IL-1β concentrations over time in periodontitis patients. The benefits observed for smokers underline the importance of oral hygiene measures, even considering the presence of this important risk factor.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Biofilms*
  • Dental Plaque / prevention & control
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gingival Crevicular Fluid / chemistry*
  • Humans
  • Interleukin-1beta / analysis*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Periodontal Index
  • Periodontitis / microbiology*
  • Periodontitis / therapy*
  • Reference Values
  • Risk Factors
  • Smoking / adverse effects*
  • Time Factors

Substances

  • Interleukin-1beta